Susan G. Komen Announces New Date and Location for 2025 Miami/Ft. Lauderdale MORE THAN PINK Walk.

Susan G. Komen announced a new date and location for the 2025 Miami/Ft. Lauderdale MORE THAN PINK Walk. The event will take place on October 4 at the Miami-Dade County Fair and Exposition. Funds raised will fuel Komen's mission to support patients with free navigation, financial aid, emotional care, and lifesaving research. Jessica Williams will serve as the Chair of this year's Walk, with a goal to unite survivors, families, and advocates to create a future without breast cancer.

Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence-driven biopharmaceutical company, has received clearance from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial to evaluate LP-184 in the treatment of triple negative breast cancer (TNBC). The clearance follows the FDA's Orphan Drug Designation for LP-184 in TNBC in 2023 and Fast Track Designation in 2024 [1].

The clinical trial, which will be conducted at select centers in the United States, India, and Nigeria, aims to assess LP-184's safety and efficacy in recurrent, advanced-stage TNBC patients. The trial will evaluate LP-184 as both a monotherapy and in combination with olaparib, a PARP inhibitor. The primary endpoints of the study include safety and efficacy parameters that could potentially support a pathway to regulatory approval [1].

LP-184 is a synthetically lethal small molecule that induces DNA double-strand breaks upon bioactivation by the enzyme prostaglandin reductase 1 (PTGR1) in cancer cells. Preclinical studies suggest that LP-184 may preferentially respond to cancers with DDR gene alterations, including TNBC [1]. The global TNBC market is estimated at $3-5 billion USD annually, with over 300,000 new cases diagnosed worldwide each year [1].

The strategic design of the clinical trial reflects both the compelling mechanistic rationale and the encouraging data supporting LP-184's potential in TNBC. Lantern Pharma's CEO and President, Panna Sharma, stated, "The strategic design of our clinical program reflects both the compelling mechanistic rationale and the encouraging data supporting LP-184's potential in TNBC" [1].

Lantern Pharma's AI-driven platform, RADR®, leverages over 100 billion oncology-focused data points and a library of 200+ advanced ML algorithms to accelerate drug discovery and development. The company's lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials [1].

References:
[1] https://finance.yahoo.com/news/lantern-advances-drug-candidate-lp-125500305.html